|
Laxman Pai, Opalesque Asia: The aggregate value of private equity-backed buyout healthcare deals in Australia grew exponentially from $0.2bn in 2016 to nearly $4bn in 2018, says Preqin.
The healthcare industry in Australia is globally recognized as a hub for world-class medical research, robust infrastructure and a strong intellectual property regime. These factors have propelled Australian healthcare into a booming industry, making waves in the country's private equity and venture capital landscape.
"It dominated the buyout deals space in 2017 and 2018 and continues to see a healthy deal pipeline to date," said Audrey Ne Win, an analyst at Preqin.
Private equity funds are also seeing new investment opportunities sprouting from emerging segments such as biotechnology and pharmaceuticals within the healthcare sector.
Venture capital funds focus on biotech and healthcare-related start-ups
The biotech and healthcare sector has traditionally been an important area of focus for Australian venture capital funds, which have backed dozens of new drugs and medical devices from initial lab research through to commercialization, and the launch of products to end-users.
The largest venture capital deals completed in the sector over the last five years have focused on medical devices and equipment.
These include the $53mn Series D funding round for Saluda Medical, led by Action Potential Venture Capital (GlaxoSmithKline's strategic venture capital f...................... To view our full article Click here
|
RSS
